Cargando…

PIWIL4 and SUPT5H combine to predict prognosis and immune landscape in intrahepatic cholangiocarcinoma

BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is a fatal primary liver cancer, and its long-term survival rate remains poor. RNA-binding proteins (RBPs) play an important role in critical cellular processes, failure of any one or more processes can lead to the development of multiple cancers. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Wenbo, Wang, Zizheng, Zhang, Xiuping, Xu, Shuai, Wang, Fei, Li, Lincheng, Deng, Zhaoda, Wang, Jing, Pan, Ke, Ge, Xinlan, Li, Chonghui, Liu, Rong, Hu, Minggen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649993/
https://www.ncbi.nlm.nih.gov/pubmed/34876138
http://dx.doi.org/10.1186/s12935-021-02310-2
_version_ 1784611113087795200
author Zou, Wenbo
Wang, Zizheng
Zhang, Xiuping
Xu, Shuai
Wang, Fei
Li, Lincheng
Deng, Zhaoda
Wang, Jing
Pan, Ke
Ge, Xinlan
Li, Chonghui
Liu, Rong
Hu, Minggen
author_facet Zou, Wenbo
Wang, Zizheng
Zhang, Xiuping
Xu, Shuai
Wang, Fei
Li, Lincheng
Deng, Zhaoda
Wang, Jing
Pan, Ke
Ge, Xinlan
Li, Chonghui
Liu, Rong
Hu, Minggen
author_sort Zou, Wenbo
collection PubMed
description BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is a fatal primary liver cancer, and its long-term survival rate remains poor. RNA-binding proteins (RBPs) play an important role in critical cellular processes, failure of any one or more processes can lead to the development of multiple cancers. This study aimed to explore pivotal biomarkers and corresponding mechanisms to predict the prognosis of patients with ICC. METHODS: The transcriptomic and clinical information of patients were collected from The Cancer Genome Atlas and Gene Expression Omnibus databases. Bioinformatic methods were used to identify survival-related and differentially-expressed biomarkers. Quantitative real-time PCR (qRT-PCR) and immunohistochemistry were used to detect the expression levels of key biomarkers in independent real-world cohorts. Subsequently, a prognostic signature was constructed that effectively distinguished patients in the high- and low-risk groups. Independent prognosis analysis was used to verify the signature’s independent predictive capabilities, and two nomograms were developed to predict survival. RESULTS: PIWIL4 and SUPT5H were identified and considered as pivotal biomarkers, and the same expression trends of upregulation in ICC were also validated via qRT-PCR and immunohistochemistry in the separate real-world sample cohorts. The prognostic signature showed good predictive capabilities according to the area under the curve. The correlation of the biomarkers with the tumour microenvironment suggested that the high riskScore was positively related to the enrichment of resting natural killer cells and activated memory CD4 + T cells. CONCLUSION: In the present study, we demonstrated that PIWIL4 and SUPT5H could be used as novel prognostic biomarkers to develop a prognostic signature. This study provides potential biomarkers of prognostic value for patients with intrahepatic cholangiocarcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02310-2.
format Online
Article
Text
id pubmed-8649993
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86499932021-12-07 PIWIL4 and SUPT5H combine to predict prognosis and immune landscape in intrahepatic cholangiocarcinoma Zou, Wenbo Wang, Zizheng Zhang, Xiuping Xu, Shuai Wang, Fei Li, Lincheng Deng, Zhaoda Wang, Jing Pan, Ke Ge, Xinlan Li, Chonghui Liu, Rong Hu, Minggen Cancer Cell Int Primary Research BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is a fatal primary liver cancer, and its long-term survival rate remains poor. RNA-binding proteins (RBPs) play an important role in critical cellular processes, failure of any one or more processes can lead to the development of multiple cancers. This study aimed to explore pivotal biomarkers and corresponding mechanisms to predict the prognosis of patients with ICC. METHODS: The transcriptomic and clinical information of patients were collected from The Cancer Genome Atlas and Gene Expression Omnibus databases. Bioinformatic methods were used to identify survival-related and differentially-expressed biomarkers. Quantitative real-time PCR (qRT-PCR) and immunohistochemistry were used to detect the expression levels of key biomarkers in independent real-world cohorts. Subsequently, a prognostic signature was constructed that effectively distinguished patients in the high- and low-risk groups. Independent prognosis analysis was used to verify the signature’s independent predictive capabilities, and two nomograms were developed to predict survival. RESULTS: PIWIL4 and SUPT5H were identified and considered as pivotal biomarkers, and the same expression trends of upregulation in ICC were also validated via qRT-PCR and immunohistochemistry in the separate real-world sample cohorts. The prognostic signature showed good predictive capabilities according to the area under the curve. The correlation of the biomarkers with the tumour microenvironment suggested that the high riskScore was positively related to the enrichment of resting natural killer cells and activated memory CD4 + T cells. CONCLUSION: In the present study, we demonstrated that PIWIL4 and SUPT5H could be used as novel prognostic biomarkers to develop a prognostic signature. This study provides potential biomarkers of prognostic value for patients with intrahepatic cholangiocarcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02310-2. BioMed Central 2021-12-07 /pmc/articles/PMC8649993/ /pubmed/34876138 http://dx.doi.org/10.1186/s12935-021-02310-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Primary Research
Zou, Wenbo
Wang, Zizheng
Zhang, Xiuping
Xu, Shuai
Wang, Fei
Li, Lincheng
Deng, Zhaoda
Wang, Jing
Pan, Ke
Ge, Xinlan
Li, Chonghui
Liu, Rong
Hu, Minggen
PIWIL4 and SUPT5H combine to predict prognosis and immune landscape in intrahepatic cholangiocarcinoma
title PIWIL4 and SUPT5H combine to predict prognosis and immune landscape in intrahepatic cholangiocarcinoma
title_full PIWIL4 and SUPT5H combine to predict prognosis and immune landscape in intrahepatic cholangiocarcinoma
title_fullStr PIWIL4 and SUPT5H combine to predict prognosis and immune landscape in intrahepatic cholangiocarcinoma
title_full_unstemmed PIWIL4 and SUPT5H combine to predict prognosis and immune landscape in intrahepatic cholangiocarcinoma
title_short PIWIL4 and SUPT5H combine to predict prognosis and immune landscape in intrahepatic cholangiocarcinoma
title_sort piwil4 and supt5h combine to predict prognosis and immune landscape in intrahepatic cholangiocarcinoma
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649993/
https://www.ncbi.nlm.nih.gov/pubmed/34876138
http://dx.doi.org/10.1186/s12935-021-02310-2
work_keys_str_mv AT zouwenbo piwil4andsupt5hcombinetopredictprognosisandimmunelandscapeinintrahepaticcholangiocarcinoma
AT wangzizheng piwil4andsupt5hcombinetopredictprognosisandimmunelandscapeinintrahepaticcholangiocarcinoma
AT zhangxiuping piwil4andsupt5hcombinetopredictprognosisandimmunelandscapeinintrahepaticcholangiocarcinoma
AT xushuai piwil4andsupt5hcombinetopredictprognosisandimmunelandscapeinintrahepaticcholangiocarcinoma
AT wangfei piwil4andsupt5hcombinetopredictprognosisandimmunelandscapeinintrahepaticcholangiocarcinoma
AT lilincheng piwil4andsupt5hcombinetopredictprognosisandimmunelandscapeinintrahepaticcholangiocarcinoma
AT dengzhaoda piwil4andsupt5hcombinetopredictprognosisandimmunelandscapeinintrahepaticcholangiocarcinoma
AT wangjing piwil4andsupt5hcombinetopredictprognosisandimmunelandscapeinintrahepaticcholangiocarcinoma
AT panke piwil4andsupt5hcombinetopredictprognosisandimmunelandscapeinintrahepaticcholangiocarcinoma
AT gexinlan piwil4andsupt5hcombinetopredictprognosisandimmunelandscapeinintrahepaticcholangiocarcinoma
AT lichonghui piwil4andsupt5hcombinetopredictprognosisandimmunelandscapeinintrahepaticcholangiocarcinoma
AT liurong piwil4andsupt5hcombinetopredictprognosisandimmunelandscapeinintrahepaticcholangiocarcinoma
AT huminggen piwil4andsupt5hcombinetopredictprognosisandimmunelandscapeinintrahepaticcholangiocarcinoma